Form 4: Disc Medicine Director Granted 10,000 Stock Options

William Richard White, a Director at Disc Medicine, Inc., was granted 10,000 stock options with an exercise price of $50.86, as disclosed in a recent SEC Form 4 filing.

Summary

• William Richard White, a Director of Disc Medicine, Inc. (IRON), was granted 10,000 stock options.
• The transaction date for this grant was June 11, 2025.
• The exercise price for these stock options is $50.86 per share.
• The options are set to expire on June 10, 2035.
• Vesting of these options is contingent upon the earlier of the Company's 2026 annual meeting of stockholders or the one-year anniversary of the grant date (June 11, 2026), subject to Mr. White's continued service as a director.

Sentiment

Score: 6

Explanation: The document reports a routine equity grant to a director. While it's a positive signal of insider alignment and confidence, it's a standard compensation event rather than a significant operational or financial announcement that would dramatically shift sentiment.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term company performance.
• An insider acquiring equity, even through a grant, can be viewed as a signal of confidence in the company's future prospects.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shares, although this is a standard aspect of equity compensation plans.

Risks

• The value of the stock options is dependent on the future market price of Disc Medicine's common stock exceeding the exercise price of $50.86.
• The options are subject to vesting conditions, meaning they could be forfeited if the director's service ceases before the vesting date.

Future Outlook

The stock option grant serves as a future incentive for the director, aligning their long-term financial interests with the company's performance and shareholder value creation. The vesting schedule indicates a commitment to continued service through at least mid-2026.

Management Comments

• The grant of stock options to William Richard White reflects the company's standard practice of equity-based compensation for its directors, designed to incentivize long-term commitment and performance.

Industry Context

Equity compensation, particularly through stock options, is a common practice in the biotechnology and pharmaceutical industries to attract and retain experienced directors and executives. This grant is consistent with typical compensation structures aimed at aligning leadership incentives with company growth and shareholder returns.

Comparison to Industry Standards

• The grant of 10,000 stock options to a director is a standard form of equity compensation in the biotech sector, comparable to practices at companies like Moderna (MRNA) or BioNTech (BNTX) which frequently use stock options and restricted stock units to compensate their non-employee directors.
• The exercise price being set at the market price on the grant date ($50.86) is a common industry standard for incentive stock options, ensuring that the options only gain value if the company's stock price appreciates post-grant.
• The vesting schedule, tied to continued service and future annual meetings, is typical for director compensation, promoting long-term engagement rather than short-term gains.

Related Party Transactions

• The grant of stock options to William Richard White, a Director of Disc Medicine, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term performance. However, future exercise could lead to minor dilution.
• Employees: No direct impact mentioned, but it reinforces the company's use of equity compensation.
• Management: The grant is part of the compensation structure for the board, incentivizing strategic oversight.

Next Steps

• The stock options will vest upon the first to occur of Disc Medicine's 2026 annual meeting of stockholders or June 11, 2026, provided William Richard White continues his service.
• Upon vesting, William Richard White will have the right to exercise the options and purchase 10,000 shares of Disc Medicine common stock at $50.86 per share, up until the expiration date of June 10, 2035.

Key Dates

Keywords

Disc Medicine, IRON, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, William Richard White